Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avacta Group plc ( (GB:AVCT) ) has issued an update.
Avacta Group’s oncology-focused Avacta Therapeutics unit is advancing its proprietary pre|CISION tumor-activated drug delivery platform, which uses FAP-mediated activation to release potent chemotherapeutic payloads directly in tumors. The company’s peptide drug conjugates aim to reduce systemic toxicity and improve dosing versus conventional antibody-drug conjugates, with its lead candidate AVA6000 already showing early activity in selected solid tumors.
At its 2026 Science Day in London, Avacta unveiled new comparative data from its AVA6103 and AVA6207 programs that reinforce the potential of its pre|CISION technology against leading marketed ADCs. AVA6103 showed markedly faster tumor penetration, higher intratumoral payload concentrations and a tumor selectivity index at least three times higher than Enhertu and Datroway, while AVA6207’s dual-payload approach delivered deeper, more durable responses than single-payload ADCs, including Enhertu, in challenging gastric cancer and FAP-driven models, underscoring competitive differentiation and strengthening the company’s intellectual property position.
Spark’s Take on AVCT Stock
According to Spark, TipRanks’ AI Analyst, AVCT is a Neutral.
Avacta Group plc’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. While there is some progress in clinical programs, financial constraints and lack of partnerships remain significant risks. The stock’s valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on AVCT stock, click here.
More about Avacta Group plc
Avacta Group plc, through its Avacta Therapeutics division, is a clinical-stage biopharmaceutical company focused on oncology. It develops drugs using its proprietary pre|CISION platform, a Fibroblast Activation Protein–activated payload delivery system designed to concentrate highly potent chemotherapies in the tumor microenvironment while sparing healthy tissue. The company’s peptide drug conjugates form a novel class of XDCs, aiming to offer advantages over traditional antibody-drug conjugates, with lead program AVA6000 targeting doxorubicin-sensitive solid tumors.
Average Trading Volume: 1,869,706
Technical Sentiment Signal: Hold
Current Market Cap: £328.1M
For detailed information about AVCT stock, go to TipRanks’ Stock Analysis page.